Intervention not reported
Time in MVPA · people with COPD, clinical stability
1 finding from 1 review
Intervention not reported
Change in time in MVPA · people with COPD, clinical stability
1 finding from 1 review
Intervention not reported
Time in MVPA · people with COPD, clinical stability
1 finding from 1 review
Intervention not reported
Time in moderate‐intensity physical activity · people with COPD, clinical stability
1 finding from 1 review
Intervention not reported
Change in time in MVPA · people with COPD, clinical stability
1 finding from 1 review
Intervention not reported
Change in time in moderate intensity physical activity · people with COPD, clinical stability
1 finding from 1 review
Intervention not reported
Time in MVPA · people with COPD, clinical stability
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg leads to lower rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (high certainty).
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (moderate certainty).
1 finding from 1 review
Time to first moderate or severe exacerbation Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg probably leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (moderate certainty).
1 finding from 1 review
Rate of exacerbations with ED visit or hospitalisations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations Eosinophilic… compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
QoL · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Exacerbations · patients with chronic obstructive pulmonary disease
Mepolizumab 750 mg showed no clear difference in number of participants experiencing an exacerbation within 6 months compared with placebo (low certainty).
2 findings from 1 review
Odds ratio 0.43 [0.06, 2.97]
1 study · 18 participants
Low
Odds ratio 9 [0.75, 108.31]
1 study · 18 participants
Low
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 750 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Health‐related quality of life (HRQL) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Lung function (FEV₁) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Moderate‐to‐severe exacerbations (rate) · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations All participants compared with placebo (moderate certainty).
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease
Benralizumab 10 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophils < 220/μL · patients with chronic obstructive pulmonary disease
Benralizumab 10 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).
1 finding from 1 review